Adage Capital Partners Gp, L.L.C. Aligos Therapeutics, Inc. Transaction History
Adage Capital Partners Gp, L.L.C.
- $52.3 Billion
- Q2 2024
A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Aligos Therapeutics, Inc. stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 5,000,000 shares of ALGS stock, worth $47 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,000,000
Previous 2,464,505
102.88%
Holding current value
$47 Million
Previous $2.42 Million
27.54%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding ALGS
# of Institutions
46Shares Held
47.2MCall Options Held
1.4KPut Options Held
300-
Armistice Capital, LLC New York, NY7.26MShares$68.2 Million0.03% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA6.39MShares$60.1 Million0.08% of portfolio
-
Deep Track Capital, LP Greenwich, CT6.1MShares$57.4 Million0.07% of portfolio
-
Vivo Capital, LLC Palo Alto, CA3.55MShares$33.3 Million0.18% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E93.12MShares$29.3 Million0.03% of portfolio
About Aligos Therapeutics, Inc.
- Ticker ALGS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,717,000
- Market Cap $373M
- Description
- Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB);...